Statement for medical professionals

15 March 2020

On the 13th March this year, the Office for Registration of Medicinal Products, Medicinal Devices and Biocidal Products has approved a change to the official approval for human use and sale of the drug ARECHIN (Chloroquiniphosphas, 250 mg tablets). The change is the addition of a new therapeutic indication: “Adjunctive therapy for beta coronavirus infections, such as SARS-CoV, MERS-CoV i SARS-CoV-2” and relevant dosage of the drug. The justification was based on the analysis of data from clinical trials conducted thusfar.

Registered dosage: beta coronavirus infections

Usually 500 mg, twice a day 1 tablet (250 mg) for 7 to 10 days, not longer than 10 days. In justified cases 2 tablets twice a day (500 mg) for 7 to 10 days, not longer than 10 days.

Recommended for all patients without a counterindication for ingestions of chloroquine.

ARECHIN is produced in the Adamed Pharma production site in Poland and will be made available for all patients requiring treatment with this drug.

Adamed Pharma, a Polish pharmaceutical company, is a socially responsible company thathas secured a reserve of the drug ARECHIN for the Polish Ministry of Health and the Material Reserves Agency.The drugwill be distributed to patients according to the orders of the Ministry of Health.

7 July 2020
CSR/Corporate social responsibility
23 November 2019